Page 1 | Search Results | Blood Advances | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evguenia Bhurtel, Omar Castaneda Puglianini, Saurabh Chhabra, Kara I. Cicero, James A. Davis, Binod Dhakal, Danai Dima, Christopher J. Ferreri, Peter A. Forsberg, Ciara L. Freeman, Megan M. Herr, Tania Jain, Murali Janakiram, Jack Khouri, Mehmet H. Kocoglu, Anupama Kumar, Yuxin Liu, Frederick Locke, Joseph P. McGuirk, Lekha Mikkilineni, Omar Nadeem, Ricardo D. Parrondo, Oren Pasvolsky, Lauren C. Peres, Sneha Purvey, Shahzad Raza, Ran Reshef, Shambavi Richard, Adriana C. Rossi, Douglas W. Sborov, Leyla Shune, Charlotte B. Wagner, Saurabh S. Zanwar, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Shaji K. Kumar, Yi Lin, Thomas G. Martin, Peter M. Voorhees, Larry D. Anderson, Jr, Andrew J. Cowan, Gurbakhash Kaur

Blood Adv (2025) 9 (9): 2336–2340.

https://doi.org/10.1182/bloodadvances.2025016131

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience

Nilesh M. Kalariya, Michelle A. T. Hildebrandt, Doris K. Hansen, Surbhi Sidana, Jack Khouri, Christopher J. Ferreri, William N. Doyle, Omar Castaneda-Puglianini, Ciara L. Freeman, Vanna Hovanky, Hitomi Hosoya, Leyla O. Shune, Krina K. Patel

Blood Adv (2024) 8 (17): 4679–4688.

https://doi.org/10.1182/bloodadvances.2024013540

Published: 2024

Includes: Supplemental data

Journal Articles

Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Blood Adv (2024) 8 (1): 251–259.

https://doi.org/10.1182/bloodadvances.2023010894

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response

Othman S. Akhtar, Biwei Cao, Xuefeng Wang, Pallawi Torka, Mohammed Al-Jumayli, Frederick L. Locke, Ciara L. Freeman

Blood Adv (2023) 7 (19): 5937–5940.

https://doi.org/10.1182/bloodadvances.2023010127

Published: 2023

Includes: Supplemental data

Journal Articles

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Blood Adv (2022) 6 (24): 6109–6119.

https://doi.org/10.1182/bloodadvances.2022008320

Published: 2022

Includes: Supplemental data

Journal Articles

The outcome of older adults with classic Hodgkin lymphoma in British Columbia

Phoebe T. M. Cheng, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Graham W. Slack, Randy D. Gascoyne, Pedro Farinha, Jeffrey W. Craig, Brian Skinnider, Don Wilson, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood Adv (2022) 6 (22): 5924–5932.

https://doi.org/10.1182/bloodadvances.2022008258

Published: 2022

Includes: Supplemental data

Journal Articles

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

Diego Villa, Eva Hoster, Olivier Hermine, Wolfram Klapper, Michal Szymczyk, André Bosly, Michael Unterhalt, Lisa M. Rimsza, Colleen A. Ramsower, Ciara L. Freeman, David W. Scott, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Martin Dreyling

Blood Adv (2022) 6 (18): 5285–5294.

https://doi.org/10.1182/bloodadvances.2022007371

Published: 2022

Journal Articles

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

Phoebe T. M. Cheng, Diego Villa, R. Petter Tonseth, David W. Scott, Alina S. Gerrie, Ciara L. Freeman, Tom Pickles, Andrea C. Lo, Pedro Farinha, Jeffrey W. Craig, Graham W. Slack, Randy D. Gascoyne, François Bénard, Don Wilson, Brian Skinnider, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood Adv (2021) 5 (18): 3647–3655.

https://doi.org/10.1182/bloodadvances.2021004375

Published: 2021

Journal Articles

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Diego Villa, Laurie H. Sehn, Kerry J. Savage, Cynthia L. Toze, Kevin Song, Wendie D. den Brok, Ciara L. Freeman, David W. Scott, Alina S. Gerrie

Blood Adv (2020) 4 (15): 3486–3494.

https://doi.org/10.1182/bloodadvances.2020002068

Published: 2020

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience

Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

The outcome of older adults with classic Hodgkin lymphoma in British Columbia

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only